Biomedical applications of L-alanine produced by Pediococcus acidilactici BD16 (alaD +)
dc.contributor.author | Sharma, Anshula | |
dc.contributor.author | Mehta, Vikrant | |
dc.contributor.author | Rani, Suman | |
dc.contributor.author | Noda, Masafumi | |
dc.contributor.author | Sugiyama, Masanori | |
dc.contributor.author | Chander, Harish | |
dc.contributor.author | Kaur, Baljinder | |
dc.date.accessioned | 2024-01-21T10:54:04Z | |
dc.date.accessioned | 2024-08-14T07:40:50Z | |
dc.date.available | 2024-01-21T10:54:04Z | |
dc.date.available | 2024-08-14T07:40:50Z | |
dc.date.issued | 2022-01-28T00:00:00 | |
dc.description.abstract | Abstract: L-alanine possesses extensive physiological functionality and tremendous pharmacological significance, therefore could be considered as potential ingredient for food, pharmaceutical, and personal care products. However, therapeutic properties of L-alanine still need to be addressed in detail to further strengthen its utilization as a viable ingredient for developing natural therapeutics with minimum side effects. Thus, the present study was aimed to explore the anticipated therapeutic potential of L-alanine, produced microbially using a lactic acid bacterial strain Pediococcus acidilactici BD16 (alaD+) expressing L-alanine dehydrogenase enzyme. The anticipated therapeutic potential of L-alanine was assessed in terms of anti-proliferative, anti-bacterial, and anti-urolithiatic properties. Anti-bacterial assays revealed that L-alanine successfully inhibited growth and in vitro proliferation of important human pathogens including Enterococcus faecalis, Escherichia coli, Klebsiella pneumonia, Staphylococcus aureus, Streptococcus mutans, and Vibrio cholerae in a concentration-dependent manner. Current investigation has also revealed its significant anti-proliferative potential against human lung adenocarcinoma (A549; IC50 7.32�?M) and mammary gland adenocarcinoma (MCF-7; IC50 8.81�?M) cells. The anti-urolithiatic potential of L-alanine was augmented over three different phases, viz., nucleation inhibition, aggregation inhibition, and oxalate depletion. Further, an in vitro cell culture�based kidney stone dissolution model using HEK293-T cells was also established to further strengthen its anti-urolithiatic potential. This is probably the first in vitro cell culture�based model which experimentally validates the immense therapeutic efficacy of L-alanine in treating urolithiasis disease. Key points: � Assessment of therapeutic potential of L-alanine produced by LAB. � L-alanine exhibited significant anti-proliferative and anti-bacterial activities. � L-alanine as potential anti-urolithiatic agent. � 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | en_US |
dc.identifier.doi | 10.1007/s00253-022-11766-9 | |
dc.identifier.issn | 1757598 | |
dc.identifier.uri | https://kr.cup.edu.in/handle/32116/4203 | |
dc.identifier.url | https://link.springer.com/10.1007/s00253-022-11766-9 | |
dc.language.iso | en_US | en_US |
dc.publisher | Springer Science and Business Media Deutschland GmbH | en_US |
dc.subject | Anti-bacterial | en_US |
dc.subject | Anti-proliferative | en_US |
dc.subject | Anti-urolithiatic | en_US |
dc.subject | Investigational drug | en_US |
dc.subject | Kidney stone dissolution | en_US |
dc.subject | L-alanine | en_US |
dc.subject | Pediococcus acidilactici BD16 | en_US |
dc.subject | Therapeutics | en_US |
dc.title | Biomedical applications of L-alanine produced by Pediococcus acidilactici BD16 (alaD +) | en_US |
dc.title.journal | Applied Microbiology and Biotechnology | en_US |
dc.type | Article | en_US |
dc.type.accesstype | Closed Access | en_US |